Contract Research Organization (CRO) Services Market to Grow at a CAGR of 9.0% During Forecast Period; Rising Awareness of Clinical Trial Outsourcing to Propel Market Growth

The global Contract Research Organization (CRO) services market size was valued at USD 92.27 billion in 2025. The market is projected to grow from USD 99.87 billion in 2026 to USD 199.28 billion by 2034, exhibiting a CAGR of 9.0% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Contract Research Organization (CRO) Services Market Size, Share & Industry Analysis, By Type (Early Phase Development Services [CMC, Preclinical, and Discovery], Clinical [Phase 1, Phase 2, Phase 3, and Phase 4], and Laboratory Services), By Application (Oncology, Neurology, Cardiology, Infectious Disease, and Renal/Nephrology), By Outsourcing Model (Full-Service Outsourcing, Functional Service Provider, and Hybrid Outsourcing), By End-User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034”.

Contract Research Organizations (CROs) are firms that offer outsourced research support, including early-phase development, clinical trials, and research management to pharmaceutical, biotechnology, and medical device companies. The market is expanding rapidly due to rising awareness of clinical trial outsourcing and the growing need for effective therapeutics.

Parexel Introduced ParexelAI to Enhance Clinical Trial Efficiency

In May 2026, Parexel International Corporation unveiled ParexelAI, its integrated AI platform. The initiative unifies its artificial intelligence capabilities across the clinical development lifecycle, including clinical site identification and selection, medical writing, clinical trial operations, regulatory submissions, and post-marketing pharmacovigilance to improve efficiency and accelerate timelines.

Surge in Clinical Trials to Propel Demand for CRO Services

To meet rising demand for advanced diagnostics and therapeutics, healthcare companies are increasingly investing in clinical trials, with trial volumes growing significantly globally. However, drug development remains lengthy, expensive, and risky, with many candidates facing termination or delays due to budget and operational challenges. To address this, small and mid-sized pharma firms are increasingly outsourcing R&D to CROs to save time and costs.

However, strict regulatory frameworks and limited funds for R&D hamper Contract Research Organization (CRO) services market growth.

Market Players Focusing on R&D to Enhance Service Offerings and Expand Market Share

In 2025, IQVIA Inc., ICON plc, Syneos Health, and Charles River Laboratories accounted for the major share of the market. These companies are enhancing their service portfolios through advanced technologies to drive revenue growth, while strengthening their dominance through collaborations with research institutes to expand operations.

Notable Industry Development

• May 2026: ICON plc strengthened its early-phase clinical footprint in the U.S. by launching a new clinical research unit in San Antonio, along with outpatient clinics in Houston and Lawrence, Kansas. The expansion aims to enhance its capacity for Phase I studies, improve patient recruitment and access, and meet growing demand for early-stage trial services.

List of Key Companies Profiled in the Report

• Medpace (U.S.)
• ICON plc (Ireland)
• IQVIA Inc. (U.S.)
• Syneos Health (U.S.)
• Novotech (Australia)
• Ergomed Group (U.K.)
• Worldwide Clinical Trials (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Microbiologics (U.S.)
• Parexel International Corporation (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-10086

Further Report Findings

• North America led the Contract Research Organization (CRO) services market share, driven by the strong presence of key market players and a rising number of clinical trials. For example, data from clinicaltrials.gov, by January 2024, a total of 477,346 clinical trials had been registered globally, with 30% (145,575) of them registered in the U.S.
• Europe is estimated to be the second-largest region in 2026, supported by increased R&D investments by pharmaceutical and biotechnology companies for novel therapeutic development.
• Based on type, in 2025, early phase development services accounted for the largest share of the CRO services market. This segment’s leadership is driven by an increasing number of pharmaceutical companies partnering with CROs that offer the necessary infrastructure and expertise to manage finance and timelines effectively. Outsourcing enables pharma companies to better manage their finances by converting fixed costs into variable costs, thereby fueling the growing demand for CRO services.

Table of Segmentation